Key Points
- Director R. Judd Jessup sold 1,262 CorVel shares at an average price of $70.64, generating $89,147.68. He retains 115,821 shares, and also sold 1,562 shares the previous day.
- CorVel shares opened at $69.24, with a $3.53 billion market capitalization, a P/E ratio of 30.77, and a 52-week range of $44.83 to $93.45.
- The company reported quarterly EPS of $0.63 on $259.93 million in revenue, while analysts’ average rating remains “Hold.” Institutional investors own 51.36% of CorVel’s outstanding stock.
CorVel Corp. (NASDAQ:CRVL - Get Free Report) Director R Judd Jessup sold 1,262 shares of the business's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $70.64, for a total transaction of $89,147.68. Following the completion of the sale, the director directly owned 115,821 shares in the company, valued at $8,181,595.44. This trade represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
R Judd Jessup also recently made the following trade(s):
- On Wednesday, August 26th, R Judd Jessup sold 1,562 shares of CorVel stock. The shares were sold at an average price of $70.71, for a total transaction of $110,449.02.
CorVel Stock Down 0.3%
NASDAQ CRVL opened at $69.24 on Friday. The stock has a market cap of $3.53 billion, a P/E ratio of 30.77 and a beta of 0.98. The company's 50-day simple moving average is $63.41 and its 200 day simple moving average is $58.22. CorVel Corp. has a twelve month low of $44.83 and a twelve month high of $93.45.
CorVel (NASDAQ:CRVL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The business services provider reported $0.63 earnings per share (EPS) for the quarter. The firm had revenue of $259.93 million during the quarter. CorVel had a net margin of 11.72% and a return on equity of 29.92%.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the company. Weiss Ratings raised CorVel from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, July 16th. Wall Street Zen raised CorVel from a "hold" rating to a "buy" rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of "Hold".
Check Out Our Latest Stock Report on CorVel
Hedge Funds Weigh In On CorVel
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of CorVel in the second quarter valued at about $321,316,000. California State Teachers Retirement System grew its holdings in CorVel by 7,962.8% during the 2nd quarter. California State Teachers Retirement System now owns 2,350,314 shares of the business services provider's stock worth $146,942,000 after acquiring an additional 2,321,164 shares during the last quarter. State Street Corp grew its holdings in CorVel by 2.7% during the 4th quarter. State Street Corp now owns 1,179,572 shares of the business services provider's stock worth $79,822,000 after acquiring an additional 30,987 shares during the last quarter. Geode Capital Management LLC grew its holdings in CorVel by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 927,845 shares of the business services provider's stock worth $62,796,000 after acquiring an additional 28,666 shares during the last quarter. Finally, Norges Bank acquired a new stake in CorVel in the 4th quarter valued at about $29,250,000. Institutional investors and hedge funds own 51.36% of the company's stock.
About CorVel
(
Get Free Report)
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers' compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel's integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company's product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
